SEC Form 4 research
| Issuer | LIGAND PHARMACEUTICALS INC |
|---|---|
| Tickers | LGND, LGNDD |
| Reporting owners | 56 |
| Officers and directors | 22 |
| Last public filing | 2026-10-06 |
| Available | Trade date | Reporting owners | Code | Shares | Price | Reported value |
|---|---|---|---|---|---|---|
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 17 | $307.74 | Not reported |
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 235 | $307.19 | Not reported |
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 404 | $306.18 | Not reported |
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 1,535 | $304.52 | Not reported |
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 1,976 | $303.54 | Not reported |
| 2026-10-06 | 2026-10-02 | Reardon Andrew | S | 833 | $302.51 | Not reported |
| 2026-09-14 | 2026-09-10 | Zimmermann Martine | S | 1,200 | $285 | Not reported |
| 2026-09-08 | 2026-09-03 | Reardon Andrew | S | 400 | $288.98 | Not reported |
| 2026-09-08 | 2026-09-03 | Reardon Andrew | S | 385 | $287.53 | Not reported |
| 2026-09-08 | 2026-09-03 | Reardon Andrew | S | 2,115 | $286.36 | Not reported |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.